NovaBridge Biosciences (NBP) Registration Filing summary

Company overview and business model

• U.S.-based global biotech focused on precision immuno-oncology agents for cancer treatment, with three clinical-stage programs: givastomig, uliledlimab, and ragistomig.

• Givastomig is the lead internal program, targeting gastric cancer, with ongoing Phase 1b trials and updates expected in Q3 2025 and H1 2026.

• Uliledlimab development is paused pending further data from a partner's Phase 2 study in China; ragistomig is managed by a collaboration partner.

• Incorporated in the Cayman Islands, principal executive offices in Rockville, MD.

Financial performance and metrics

• As of April 14, 2025, public float was $64.0 million, based on 153,940,774 ordinary shares held by non-affiliates at $0.95 per ADS.

• 187,452,495 ordinary shares outstanding as of December 31, 2024; excludes options and RSUs.

• Cash and cash equivalents as of December 31, 2024: $68.3 million actual, $88.3 million as adjusted for the offering.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for pipeline development, general corporate purposes, and working capital.

• Management retains broad discretion over allocation and timing of expenditures.

• Pending use, proceeds may be invested in short-term, investment-grade, interest-bearing securities.